👏Will talk on: #AI driven reverse #translation & first-in-class #multispecifics to blunt #immunotherapy #resistant #tumor microenvironment" #ImmunoMarkSummit
✊See: immunomarksummit.com
🔥Will discuss @kuleuvenuniversity.bsky.social innovation platform: #RETROFIT & its lead #cancer #therapy: #TriMA

OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers » ModeX Therapeutics First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein  Two MDX2004 abstracts accepted for poster

We are excited to announce we have
initiated Phase 1/2a clinical trial (NCT07110584) with MDX2004, a first-in-class trispecific antibody-fusion protein for oncology and immune disorders. See here for more bit.ly/436FmEW
$OPK #multispecifics #antibodies

Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial - Nature Medicine In the randomized phase 1b/2 Morpheus-Melanoma trial evaluating various neoadjuvant immune checkpoint inhibitor regimens in patients with resectable stage III melanoma, tobemstomig, an anti-PD-1/anti-LAG-3 bispecific antibody, showed the highest pathologic response rate with a better safety profile than the standard treatment approach of ipilimumab plus nivolumab.

💪#Power of #bispecifics in #cancer #patient #treatment?
✴️Anti-#PD1 x #LAG3 #bispecific had similar anti-#tumour #efficacy vs anti-#PD1/anti-#CTLA4 #combo but with better #safety #profile
⏲️Time to move #multispecifics vs #macrophages where #monos failed!
www.nature.com/articles/s41...